Biocon Biologics to launch

Biocon Biologics to launch an IPO in 2 years

Biocon Biologics to launch an IPO in 2 years

Bengaluru: Biocon Biologics to launch an IPO to raise $200 million. So then, in the coming months, the raised amount might come in use for its biologics subsidiary. Mr. Kiran Mazumdar-Shaw, the Chairman, said that it might list in on the capital markets in around 2 years.

Previously, Biocon said venture capital firm True North might invest Rs 536.25 crores to catch up 2.44% stake in the biosimilar subsidiary. Besides, the valuation of Biocon Biologics stood at Rs 21,450 crores on a pre-money equity basis. Mr. Mazumdar-Shaw stated that the benchmark valuation for Biologics stood at $3 billion. Also, the embedded value of Syngene shows Biocon stock remained undervalued. Besides, Biocon started interacting with global investors. Such as the Singapore government-owned Temasek Holdings and also the UK government‘s investment arm CDC for future rounds of fundraising. 

Despite this, True North likely to take part in those rounds. However, Biocon has a combined stake in Biocon Biologics. Moreover, it has clocked a revenue of around $200 million last fiscal year. Also, now chasing a revenue target of $1 billion in FY21-22. 

Furthermore, Biocon Biologics IPO might commence on the lines of Biocon’s contract research arm Syngene’s listing in 2015. 

Related posts

SBI Cards and Payments plans to hit JSW Steel, M&M

nagalavanya

SEBI to compel SWS for an exit offer to IPO investors

kanthi

Druva’s IPO Plan: SaaS Startup Druva Plans for an IPO

sadhana